Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Neoplasms 1 Muscle Invasive Bladder Cancer 1 Disease 1 Carcinoma, Renal Cell 1

Interventions

Blood Specimen Collection 3 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3 Surveys and Questionnaires 2 Prednisone 2 Positron-Emission Tomography 2 Magnetic Resonance Imaging 2 Injections 2 vistusertib 1 technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1 pembrolizumab 1 lortalamine 1 ioflupane 1 gossypol acetic acid 1 carbon-11 acetate 1 abiraterone 1 Waiting Lists 1 Urine Specimen Collection 1 Urination 1 Transcutaneous Electric Nerve Stimulation 1 Therapeutics 1 Specimen Handling 1 Referral and Consultation 1 Prostatectomy 1 Preoperative Exercise 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Observation 1 Music Therapy 1 Multiparametric Magnetic Resonance Imaging 1 Mitomycin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Disease × vistusertib × Genitourinary × Clear all

NCT02064608 2019-07-17

CaNCaP02

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed

Disease, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡